BCG Therapy for Bladder Cancer — The Oldest Immunotherapy Still in Use

BCG works by causing a controlled infection inside your bladder. It is a live, weakened bacterium. Once it is instilled, it sticks to the bladder lining, immune cells rush in, and the inflammation that follows clears microscopic cancer left behind after surgery. Your immune system does the treating. BCG only starts it.

BCG stands for Bacillus Calmette-Guerin. It is a weakened strain of a cattle tuberculosis bacterium, grown and attenuated until it can no longer cause tuberculosis in a healthy person. It is not a chemotherapy drug. It is not an antibody. It is not given into a vein. What arrives at your appointment is a small bag of cloudy liquid that goes into the bladder through a catheter and stays there for about two hours.

The sequence inside the bladder is well described in NCCN and ESMO patient-education material, and it is worth knowing because it explains almost every side effect on this page.

• It sticks — BCG binds to a protein called fibronectin in the bladder wall, and to any cancer cells left behind after the visible tumour was resected.
• It gets taken in — cells of the bladder lining swallow the bacteria and display fragments of them on their surface, like a flag raised over the tissue.
• The immune system arrives — neutrophils, macrophages, dendritic cells, natural killer cells and T cells move into the bladder wall and release cytokines. This is a genuine, deliberate inflammation, not a side effect of one.
• Residual cancer is cleared as part of that reaction — microscopic disease that surgery could not see is dealt with by immune cells, not by a drug that poisons dividing cells.
• Some memory persists — the local immune response does not vanish the moment the treatment ends, which is the reasoning behind maintenance doses rather than a single course.

One distinction is worth holding on to. BCG is non-specific immune stimulation: it shouts loudly inside one organ and the immune system responds. The newer classes work by other routes — releasing a stand-down signal on immune cells, or physically bringing an immune cell and a cancer cell together. Different mechanisms, different side-effect patterns, different settings. No claim is made here that any one of them performs better than another.

Because almost all of the action happens inside the bladder, almost all of the expected side effects are urinary. That is not a coincidence — it follows directly from the mechanism above.

Because it is older than the vocabulary. BCG entered bladder cancer practice in the 1970s, long before immunotherapy became a familiar word in cancer care. It is inexpensive, it is given in a urology room rather than a chemotherapy day-care unit, and it arrives in a catheter rather than an infusion line. None of that makes it any less immunotherapy.

• It predates the term — immunotherapy became everyday cancer language only after the newer infused classes arrived in the 2010s. By then BCG had already been standard for decades, under its own name.
• It sits with urology, not medical oncology — instillations are usually done by a urology team, so the framing patients hear is procedural rather than conceptual.
• It is inexpensive — BCG is among the least costly treatments in cancer care, and India is one of the world’s major producers of it. Cost varies by centre and by supply, and any figure quoted to you is indicative only, as of August 2026.
• It is delivered locally — no drip stand, no port, no infusion chair. The visual language that patients associate with cancer treatment is simply absent.
• Nothing markets it — it is an old, off-patent biological with no campaign behind it, so it never picked up the label that newer classes were introduced with.

Knowing the correct name for it changes the questions you can ask. If it is immunotherapy, then it is reasonable to ask how the immune reaction is being monitored, what an unexpected fever means, and how this class differs from the ones you may have read about online.

Risk grouping follows the categories used in current NCCN and ESMO guidance and applied in Indian practice. Your urologist assigns your group from the pathology report after resection — this table is orientation, not an allocation.

1. 1

   Surgery comes first

   BCG is not the first step. The visible tumour is removed by transurethral resection, through the urethra, with no cut on the abdomen. BCG then treats what may remain microscopically. A gap of two to four weeks lets the bladder lining heal, because instilling BCG into a raw bladder risks the bacteria entering the bloodstream.

2. 2

   A check before every single dose

   Urine is checked for infection before each instillation. If there is an active urinary infection, visible blood, or the catheter goes in with difficulty, that week’s dose is postponed rather than pushed through. You are usually asked to reduce fluids for a few hours beforehand so the dose is not diluted.

3. 3

   The instillation itself

   A thin catheter is passed, about 50 ml of liquid goes in, and the catheter comes out. It takes a few minutes. No needle, no drip, no sedation.

4. 4

   Two hours of holding it in

   You keep the liquid in the bladder for around two hours. Many centres ask you to change position every fifteen minutes or so, so the fluid reaches the whole lining. You then pass urine sitting down. This waiting period is the treatment; there is nothing else happening.

5. 5

   Six hours of simple home precautions

   For about six hours afterwards your urine contains live BCG. Pass urine sitting down, add roughly a cup of household bleach to the toilet, leave it fifteen to twenty minutes, then flush. Wash your hands. Drink plenty of fluids for the rest of the day. Normal contact with your family is safe.

6. 6

   Induction, then maintenance

   Six weekly doses is induction. Maintenance is usually three weekly doses repeated at intervals over the following months — about a year in intermediate-risk disease and up to three years in high-risk disease under current NCCN and ESMO guidance. Cystoscopy surveillance runs alongside it throughout.

Whether intravesical BCG is offered at any given centre depends on its urology service and on BCG supply, which has been intermittent worldwide. Ask your treating team directly where your instillations would be done and who would supervise them.

Local symptoms often become more noticeable across successive doses rather than less. That pattern is expected and is not by itself a reason to stop. What matters is that you report every symptom before the next instillation, because your urologist uses that to decide whether to give, delay or reduce the next dose. Severe reactions are uncommon, and the ones that matter are recognisable.

If the table raised a question, the class pages go further. Bispecific antibodies and T-cell engagers explains the two-handed mechanism and why the first doses are watched so carefully. Immunomodulators: tablets that work on the immune system covers the oral class that many patients do not realise is immune-directed at all. And antibody-drug conjugates: immunotherapy or chemotherapy? settles a naming confusion that comes up constantly.

No comparative claim is made here. These classes are used in different cancers, at different stages, on different evidence, and they are not alternatives to one another in any single patient’s situation.

• Bispecific Antibodies and T-Cell Engagers — the class that holds an immune cell and a cancer cell together, and why the first doses are given under close watch.
• Immunomodulators: Tablets That Work on the Immune System — the oral immune-directed class, and why a tablet can be immunotherapy just as a bladder instillation can.
• Antibody-Drug Conjugates: Immunotherapy or Chemotherapy? — a straight answer to the naming question that BCG raises from the other direction.
• Immunotherapy at CION Cancer Clinics — the hub page: biomarker testing, day-care administration, monitoring and support in one place.

This page explains a class of treatment from a scientific standpoint. It is general information, not a treatment recommendation, and not a substitute for consultation with your own urologist and oncologist. No brand or product is named or endorsed here, and no comparison of one product against another is made. Immunotherapy is administered as day care at CION centres; response-assessment PET-CT is coordinated at partner imaging centres. CION does not provide CAR-T or cell therapy. Any cost mentioned is indicative only, as of August 2026. Only your treating team, reviewing your complete case, can say whether any of this applies to you.

Every family wants to know what is being put in

Asking what a treatment is and how it works before agreeing to it is not doubt — it is good sense. Our team takes the time to explain the mechanism, the schedule and the honest limits.